As the tradies market embraces digitalisation, Hipages is positioning itself to capitalise and capture the $141 billion local industry.
Hillgrove Resources is aiming to become the next ASX copper success story, as it explores and grows its reborn Kanmantoo mine.
Rhythm Biosciences has raised $3.5m and plans to commercialise the second generation of its bowel cancer blood test Colostat in 2025.
With M&A and IPOs, corporate activity in ASX lithium companies is making a return of sorts.
As Donald Trump’s second term in the Oval Office looms, global markets face a seismic shift with opportunities and risks both firmly in play, writes Nigel Green.
